Dynamic 3D Analysis of Myocardial Sympathetic Innervation: An Experimental Study Using 123I-MIBG and a CZT Camera

Data on the in vivo myocardial kinetics of 123I-metaiodobenzylguanidine (123I-MIBG) are scarce and have always been obtained using planar acquisitions. To clarify the normal kinetics of 123I-MIBG in vivo over time, we designed an experimental protocol using a 3-dimensional (3D) dynamic approach with a cadmium zinc telluride (CZT) camera. Methods: We studied 6 anesthetized pigs (mean body weight, 37 ± 4 kg). Left ventricular myocardial perfusion and sympathetic innervation were assessed using 99mTc-tetrofosmin (26 ± 6 MBq), 123I-MIBG (54 ± 14 MBq), and a CZT camera. A normal perfusion/function match on gated SPECT was the inclusion criterion. A dynamic acquisition in list mode started simultaneously with the bolus injection of 123I-MIBG, and data were collected every 5 min for the first 20 min and then at acquisition steps of 30, 60, 90, and 120 min. Each step was reconstructed using dedicate software and reframed (60 s/frame). On the reconstructed transaxial slice that best showed the left ventricular cavity, regions of interest were drawn to obtain myocardial and blood pool activities. Myocardial time–activity curves were generated by interpolating data between contiguous acquisition steps, corrected for radiotracer decay and injected dose, and fitted to a bicompartmental model. Time to myocardial maximum signal intensity (MSI), MSI value, radiotracer retention index (RI, myocardial activity/blood pool integral), and washout rate were calculated. The mediastinal signal was measured and fitted to a linear model. Results: The myocardial MSI of 123I-MIBG was reached within 5.57 ± 4.23 min (range, 2–12 min). The mean MSI was 0.426% ± 0.092%. Myocardial RI decreased over time and reached point zero at 176 ± 31 min (range, 140–229 min). The ratio between myocardial and mediastinal signal at 15 and 125 min and extrapolated at 176 and 4 h was 5.45% ± 0.61%, 4.33% ± 1.23% (not statistically significant vs. 15 min), 3.95% ± 1.46% (P < 0.03 vs. 125 min), and 3.63% ± 1.64% (P < 0.03 vs. 176 min), respectively. Mean global washout rate at 125 min was 15% ± 14% (range, 0%–34%), and extrapolated data at 176 min and 4 h were 18% ± 18% (range, 0.49%–45%) and 25% ± 23% (range, 1.7%–56.2%; not statistically significant vs. 176 min), respectively. Conclusion: 3D dynamic analysis of 123I-MIBG suggests that myocardial peak uptake is reached more quickly than previously described. Myocardial RI decreases over time and, on average, is null about 3 h after injection. The combination of an early peak and variations in delayed myocardial uptake could result in a wide physiologic range of washout rates. Mediastinal activity appears to be constant over time and significantly lower than previously described in planar studies, resulting in a higher heart-to-mediastinum ratio.

[1]  Paolo Marzullo,et al.  Feasibility of [123I]-meta-iodobenzylguanidine dynamic 3-D kinetic analysis in vivo using a CZT ultrafast camera: preliminary results , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  A. Arbab,et al.  Parameters of dynamic and static iodine-123-MIBG cardiac imaging. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  D. Berman,et al.  Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. , 1997, Journal of the American College of Cardiology.

[4]  S. Nekolla,et al.  Evaluation of sympathetic nerve terminals with [(11)C]epinephrine and [(11)C]hydroxyephedrine and positron emission tomography. , 2000, Circulation.

[5]  C. Reiners,et al.  Effect of specific activity on cardiac uptake of iodine-123-MIBG. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  D. Wieland,et al.  Assessment of cardiac sympathetic nerve integrity with positron emission tomography. , 2001, Nuclear medicine and biology.

[7]  Kyung-Han Lee,et al.  Effects of anesthetic agents on cellular 123I-MIBG transport and in vivo 123I-MIBG biodistribution , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  G. Hutchins,et al.  Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography. , 1993, Journal of the American College of Cardiology.

[9]  J. Glowniak,et al.  Evaluation of metaiodobenzylguanidine heart and lung extraction fraction by first-pass analysis in pigs. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  T. Nakata,et al.  A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. , 2013, JACC. Cardiovascular imaging.

[11]  M. Cerqueira,et al.  Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. , 2010, Journal of the American College of Cardiology.

[12]  A. Teresińska Metaiodobenzylguanidine scintigraphy of cardiac sympathetic innervation. , 2012, Nuclear medicine review. Central & Eastern Europe.

[13]  J. Corbett,et al.  Radioiodinated tracers for myocardial imaging. , 1990, Seminars in nuclear medicine.

[14]  H. Verberne,et al.  Vascular time-activity variation in patients undergoing 123I-MIBG myocardial scintigraphy: implications for quantification of cardiac and mediastinal uptake , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  D. Le Guludec,et al.  Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology , 2010, European Journal of Nuclear Medicine and Molecular Imaging.